RALLYBIO CORPORATION Financing Cash Flow
RALLYBIO CORPORATION (RLYB) reported Financing Cash Flow of $134.00 thousand for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-26
- RALLYBIO CORPORATION net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $131.00K, a 1210.00% increase year-over-year.
- RALLYBIO CORPORATION net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $3.00K.
- RALLYBIO CORPORATION net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $6.00K, a 66.67% decline year-over-year.
- RALLYBIO CORPORATION net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00.
- RALLYBIO CORPORATION net cash provided by (used in) financing activities for fiscal 2023 was $143.00K, a 99.72% decline from fiscal 2022.
- RALLYBIO CORPORATION net cash provided by (used in) financing activities for fiscal 2022 was $51.08M, a 38.44% decline from fiscal 2021.
- RALLYBIO CORPORATION net cash provided by (used in) financing activities for fiscal 2021 was $82.97M, a 42.74% decline from fiscal 2020.
- RALLYBIO CORPORATION net cash provided by (used in) financing activities for fiscal 2020 was $144.89M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $131.00K derived: S-4/A 6 month − S-4 3 month · filed 2026-08-26 | $134.00K S-4/A · filed 2026-08-26 | $140.00K derived: sum of 3 quarters · filed 2026-08-26 | $140.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | $3.00K S-4 · filed 2026-07-15 | $9.00K derived: sum of 2 quarters · filed 2026-08-26 | $9.00K derived: sum of 3 quarters · filed 2026-08-26 | $19.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | $6.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $6.00K derived: sum of 2 quarters · filed 2026-08-26 | $16.00K derived: sum of 3 quarters · filed 2026-08-26 | $16.00K S-4/A · filed 2026-08-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − S-4/A 6 month · filed 2025-11-06 | $10.00K derived: sum of 2 quarters · filed 2026-08-26 | $10.00K 10-Q · filed 2025-11-06 | $28.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-06-30 | $10.00K derived: S-4/A 6 month − S-4 3 month · filed 2026-08-26 | $10.00K S-4/A · filed 2026-08-26 | $28.00K derived: sum of 3 quarters · filed 2026-08-26 | $17.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-03-31 | $0.00 S-4 · filed 2026-07-15 | $18.00K derived: sum of 2 quarters · filed 2026-08-26 | $7.00K derived: sum of 3 quarters · filed 2026-08-26 | $5.20M derived: sum of 4 quarters · filed 2026-08-26 |
| 2024-12-31 | $18.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $7.00K derived: sum of 2 quarters · filed 2026-08-26 | $5.20M derived: sum of 3 quarters · filed 2026-08-26 | $5.20M S-4/A · filed 2026-08-26 |
| 2024-09-30 | -$11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.18M derived: sum of 2 quarters · filed 2025-11-06 | $5.18M 10-Q · filed 2025-11-06 | $5.25M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $5.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $5.19M 10-Q · filed 2025-08-07 | $5.26M derived: sum of 3 quarters · filed 2025-08-07 | $5.26M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $72.00K derived: sum of 2 quarters · filed 2025-05-08 | $72.00K derived: sum of 3 quarters · filed 2025-05-08 | $282.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $72.00K derived: sum of 2 quarters · filed 2025-03-13 | $282.00K derived: sum of 3 quarters · filed 2025-03-13 | $143.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $210.00K derived: sum of 2 quarters · filed 2024-11-07 | $71.00K 10-Q · filed 2024-11-07 | $51.23M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $210.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $71.00K 10-Q · filed 2024-08-08 | $51.23M derived: sum of 3 quarters · filed 2024-08-08 | $51.15M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$139.00K 10-Q · filed 2024-05-09 | $51.02M derived: sum of 2 quarters · filed 2024-05-09 | $50.94M derived: sum of 3 quarters · filed 2024-05-09 | $50.94M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $51.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $51.08M derived: sum of 2 quarters · filed 2024-03-12 | $51.08M derived: sum of 3 quarters · filed 2024-03-12 | $51.08M 10-K · filed 2024-03-12 |
| 2022-09-30 | -$79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$79.00K derived: sum of 2 quarters · filed 2023-11-09 | -$79.00K 10-Q · filed 2023-11-09 | -$1.70M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | -$1.62M derived: sum of 3 quarters · filed 2023-08-08 | $83.63M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | -$1.62M derived: sum of 2 quarters · filed 2023-05-09 | $83.63M derived: sum of 3 quarters · filed 2023-05-09 | $82.97M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $83.63M derived: sum of 2 quarters · filed 2023-03-06 | $82.97M derived: sum of 3 quarters · filed 2023-03-06 | $82.97M 10-K · filed 2023-03-06 |
| 2021-09-30 | $85.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $84.59M derived: sum of 2 quarters · filed 2022-11-07 | $84.59M 10-Q · filed 2022-11-07 | $84.58M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$663.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$663.00K 10-Q · filed 2022-08-08 | -$673.00K derived: sum of 3 quarters · filed 2022-08-08 | -$675.00K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | -$10.00K derived: sum of 2 quarters · filed 2022-05-10 | -$12.00K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$12.00K derived: sum of 2 quarters · filed 2022-03-15 | $144.89M 10-K · filed 2022-03-15 | |
| 2020-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $144.90M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $144.90M 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |